Pimavanserin tartrate (ACP-103)
ACP-103-014
Phase 3 small_molecule completed
Quick answer
Pimavanserin tartrate (ACP-103) for Parkinson's Disease Psychosis is a Phase 3 program (small_molecule) at ACADIA PHARMACEUTICALS INC with 4 ClinicalTrials.gov record(s).
Program details
- Company
- ACADIA PHARMACEUTICALS INC
- Indication
- Parkinson's Disease Psychosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed